Parabilis Medicines
Parabilis Medicines Raises $305M Series F | Precision Medicine Platform
Parabilis Medicines Closes $305M Series F
Parabilis Medicines, a biotechnology company developing precision medicines, has raised $305 million in Series F funding.
The round was co-led by RA Capital Management, Fidelity, and Janus Henderson Investors.
Key Highlights
- Late-stage biotech funding
- Focus on precision medicine
- Strong institutional backing
Company Overview
Parabilis Medicines is advancing a pipeline of precision medicines targeting genetic drivers of disease, with multiple programs in clinical development.
Company Info
Investors (3)
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free